• 1
    Cavazzana AO, Prayer-Galetti T, Sangiorgio A, et al. DNA content, nuclear grading and early tumor progression in renal cell cancer: a prospective study on frozen specimens. Eur Urol. 1992; 22: 311315.
  • 2
    de Riese WT, Crabtree WN, Allhoff EP, et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol. 1993; 11: 18041808.
  • 3
    Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors in renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 994996.
  • 4
    Henson DE, Fielding LP, Grignon DJ, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med. 1995; 119: 11091112.
  • 5
    Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 1320.
  • 6
    Kaiser U, Hansmann ML, Papadopoulos I. Does the immunophenotype of renal cell carcinoma correlate with its clinical stage? Urol Int. 1991; 47: 194198.
  • 7
    Asero R, Origgi L, Crespi S, Bertetti E, D'Agostino P, Riboldi P. Autoantibody to proliferating cell nuclear antigen (PCNA) in SLE: a clinical and serological study. Clin Exp Rheumatol. 1987; 5: 241246.
  • 8
    Cronin KJ, Williams NN, Kerin MJ, et al. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J Urol. 1994; 152: 834836.
  • 9
    Liu LF, Liu CC, Alberts BM. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell. 1980; 19: 697707.
  • 10
    Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell-cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991; 2: 209214.
  • 11
    Rudolph P, Olsson H, Bonatz G, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol. 1999; 187: 207216.
  • 12
    Yabuki N, Sasano H, Kato K, et al. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol. 1996; 149: 9971007.
  • 13
    Shuin T, Sano K. The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma. Anticancer Res. 1994; 14: 26212626.
  • 14
    Rudolph P, Alm P, Heidebrecht HJ, et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst. 1999; 91: 271278.
  • 15
    Heidebrecht HJ, Buck F, Steinmann J, Sprenger R, Wacker HH, Parwaresch R. p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood. 1997; 90: 226233.
  • 16
    SobinLH, WittekindC, editors. TNM classification of malignant tumors, 5th ed. New York: John Wiley & Sons, 1997.
  • 17
    Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986; 181: 125143.
  • 18
    Hofmockel G, Tsatalpas P, Muller H, et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer. 1995; 76: 296306.
  • 19
    Heidebrecht HJ, Buck F, Haas K, Wacker HH, Parwaresch R. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the “Ki-67” proteins. Cell Prolif. 1996; 29: 413425.
  • 20
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 21
    Cox DR. Regression models and life tables with discussion. J R Stat Soc B. 1972; 34: 187220.
  • 22
    Stauffer M. Nephrogenic hepatosplenomegaly. Gastroenterology. 1961; 40: 694.
  • 23
    Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003; 88: 348353.
  • 24
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 25302540.
  • 25
    Symbas NP, Townsend MF, El Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000; 86: 203207.
  • 26
    O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol. 2002; 168: 13781380.
  • 27
    Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res. 1987; 47: 41304133.
  • 28
    Karpatkin S, Pearlstein E, Salk PL, Yogeeswaran G. Role of platelets in tumor cell metastases. Ann NY Acad Sci. 1981; 370: 101118.
  • 29
    Westermark B, Heldin CH. Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncol. 1993; 32: 101105.
  • 30
    Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol. 2000; 34: 246251.
  • 31
    Strohmeyer T, Ackermann R. Classic and modern prognostic indicators in renal cell carcinoma. Review of the literature. Urol Int. 1991; 47: 203212.
  • 32
    Schips L, Lipsky K, Zigeuner R, et al. Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology. 2003; 62: 10241028.
  • 33
    Cindolo L, De La TA, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003; 92: 901905.
  • 34
    Chow WH, Gridley G, Fraumeni JF Jr., Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000; 343: 13051311.
  • 35
    Parker A, Freeman LB, Cantor K, Lynch C. Self-report of smoking, obesity and hypertension history and survival among a cohort of Iowa renal cell carcinoma cases. Ann Epidemiol. 2000; 10: 467468.
  • 36
    Bell E. Renal disease. Philadelphia: Lea & Febiger, 1950.
  • 37
    Di Silverio F, Casale P, Colella D, Andrea L, Seccareccia F, Sciarra A. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer. 2000; 88: 835843.
  • 38
    Goldstein NS. The current state of renal cell carcinoma grading. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 977980.
  • 39
    Delahunt B, Bethwaite PB, Thornton A, Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer. 1995; 75: 27142719.
  • 40
    Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur Urol. 1997; 31: 350355.
  • 41
    Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer. 1997; 80: 17681775.
  • 42
    Papadopoulos I, Weichert-Jacobsen K, Wacker HH, Sprenger E. Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study. Eur Urol. 1997; 31: 4953.
  • 43
    Haitel A, Wiener HG, Migschitz B, Marberger M, Susani M. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas? Am J Clin Pathol. 1997; 107: 229235.
  • 44
    Rijken AM, Umezawa A, van Gulik TM, et al. Prognostic value of cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically resectable, distal bile duct carcinoma. Ann Surg Oncol. 1998; 5: 699705.
  • 45
    Kawamura K, Kobayashi Y, Tanaka T, Ikeda R, Fujikawa-Yamamoto K, Suzuki K. Intranuclear localization of proliferating cell nuclear antigen during the cell cycle in renal cell carcinoma. Anal Quant Cytol Histol. 2000; 22: 107113.
  • 46
    Khurana KK, Truong LD, Verani RR. Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: comparison with classic renal cell carcinoma. Mod Pathol. 1998; 11: 339346.
  • 47
    Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol. 1998; 15: 6876.